Prevalence of undiagnosed COPD in male patients with coronary artery disease: a cross-sectional study in Jordan

Basheer Y Khassawneh, Shaher M Samrah, Mohamad I Jarrah, Rasheed K Ibdah, Ali M Ibnian, Abdel-Hameed W Al-Mistarehi, Aseel A Zghayer, Saddam I Abuqudairi, Yousef S Khader, Basheer Y Khassawneh, Shaher M Samrah, Mohamad I Jarrah, Rasheed K Ibdah, Ali M Ibnian, Abdel-Hameed W Al-Mistarehi, Aseel A Zghayer, Saddam I Abuqudairi, Yousef S Khader

Abstract

Purpose: COPD and coronary artery disease (CAD) are common chronic diseases with shared risk factors. COPD continues to be largely underdiagnosed and undertreated. We aimed to describe the prevalence and predictors of undiagnosed COPD in Jordanian men with CAD.

Patients and methods: In a cross-sectional study conducted at a referral center in Jordan, male patients who underwent coronary angiography for suspected CAD and reported ≥10 pack-year of cigarette smoking were recruited. Pre- and post-bronchodilator spirometry was undertaken for all participants, and COPD was defined as post-bronchodilator FEV1/FVC <70%. The finding of ≥50% coronary luminal narrowing confirmed the presence of CAD.

Results: Spirometry was undertaken for 376 men with mean age of 56.02±10.55 years, and 72.6% were active cigarettes smokers with a mean pack-year of 55.89±34.25. A CAD diagnosis was confirmed in 300 (79.8%) men. Spirometric criteria for COPD were met in 76 (15.7%) patients, of whom 91.5% were not previously diagnosed. COPD-related symptoms were common: chronic cough (44.4%), dyspnea (66.2%), and wheezes (27.9%). COPD was more common in patients with (18.0%) compared to patients without (6.6%) CAD (P=0.014). Multivariate logistic regression showed that the risk of COPD was higher in patients with CAD (OR 3.16, 95% CI, 1.10-9.09, P=0.033) and in those with chronic bronchitis (OR 13.07, 95% CI, 6.69-25.52, P<0.001).

Conclusion: There was a high prevalence of COPD among male patients with CAD and most were underdiagnosed despite having respiratory symptoms. Male smokers with CAD and respiratory symptoms should be evaluated for airflow limitation and the presence of COPD.

Keywords: COPD; airflow limitation; cardiovascular disease; coronary catheterization; spirometry.

Conflict of interest statement

The authors report no conflicts of interest in this work.

© 2018 Khassawneh et al.

Figures

Figure 1
Figure 1
Flow chart of study participants showing excluded patients at different stages of the study.

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). The Global Strategy for the Diagnosis, Management and Prevention of COPD; 2017. Available from: . Accessed May 20, 2017.
    1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412.
    1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35(42):2929–2959.
    1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146–e603.
    1. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065–1072.
    1. Maclay JD, Macnee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143(3):798–807.
    1. Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178.
    1. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulm Med. 2012;12:26.
    1. Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest. 2010;137(2):333–340.
    1. Wada H, Nakano Y, Nagao T, et al. Detection and prevalence of chronic obstructive pulmonary disease in a cardiovascular clinic: evaluation using a hand held FEV1/FEV6 meter and questionnaire. Respirology. 2010;15(8):1252–1258.
    1. Onishi K, Yoshimoto D, Hagan GW, Jones PW. Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan. Int J Chron Obstruct Pulmon Dis. 2014;9:563–568.
    1. Almagro P, Lapuente A, Pareja J, et al. Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study. Int J Chron Obstruct Pulmon Dis. 2015;10:1353–1361.
    1. Zhang M, Cheng YJ, Zheng WP, et al. Impact of Chronic Obstructive Pulmonary Disease on Long-Term Outcome in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Biomed Res Int. 2016;2016:8212459–6.
    1. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–725.
    1. Aït-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ. 2001;79(10):971–979.
    1. Tageldin MA, Nafti S, Khan JA, et al. Distribution of COPD-related symptoms in the Middle East and North Africa: results of the BREATHE study. Respir Med. 2012;106(Suppl 2):S25–S32.
    1. Al Omari M, Khassawneh BY, Khader Y, Dauod AS, Bergus G. Prevalence of chronic obstructive pulmonary disease among adult male cigarettes smokers: a community-based study in Jordan. Int J Chron Obstruct Pulmon Dis. 2014;9:753–758.
    1. Ahmed AH, Yagoub TE, Muthana F. Prevalence of chronic obstructive pulmonary disease in patients with catheter-diagnosed coronary artery disease. Ann Thorac Med. 2009;4(2):91–92.
    1. Ullah R, Salam S, Ghaffar T, Muhammad R, Khan I. Frequency Of Undiagnosed Chronic Obstructive Pulmonary Disease In Patients With Coronary Artery Disease. J Ayub Med Coll Abbottabad. 2017;29(2):285–288.
    1. van der Molen T, Willemse BW, Schokker S, Ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003;1(1):13.
    1. Global Initiative for Chronic Obstructive Lung Disease. GOLD spirometry guide; 2010. Available from: . Accessed May 20, 2017.
    1. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968.
    1. Chen W, Thomas J, Sadatsafavi M, Fitzgerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639.
    1. Finkelstein J, Cha E, Scharf S. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337–349.
    1. Franssen FME, Soriano JB, Roche N, et al. Lung Function Abnormalities in Smokers with Ischemic Heart Disease. Am J Respir Crit Care Med. 2016;194(5):568–576.
    1. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956–962.
    1. Uzaslan E, Mahboub B, Beji M, et al. The burden of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE study. Respir Med. 2012;106(Suppl 2):S45–S59.
    1. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Exacerbation Of Chronic Obstructive Pulmonary Disease: Pan-Airway and Systemic Inflammatory Indices. Proc Am Thorac Soc. 2006;3(6):481–482.
    1. Eickhoff P, Valipour A, Kiss D, et al. Determinants of Systemic Vascular Function in Patients with Stable Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2008;178(12):1211–1218.
    1. Huiart L, Ernst P, Suissa S. Cardiovascular Morbidity and Mortality in COPD. Chest. 2005;128(4):2640–2646.
    1. Pizarro C, Herweg-Steffens N, Buchenroth M, et al. Invasive coronary angiography in patients with acute exacerbated COPD and elevated plasma troponin. Int J Chron Obstruct Pulmon Dis. 2016;11:2081–2089.
    1. Almagro P, de La Sierra A, Acosta E, et al. Spirometrically Confirmed Chronic Obstructive Pulmonary Disease Worsens Long-Term Prognosis after Percutaneous Coronary Intervention. Am J Respir Crit Care Med. 2018;197(6):824–826.
    1. Decramer ML, Hanania NA, Lotvall JO, Yawn BP. The safety of longacting beta2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:53–64.
    1. Zhang W, Zhang Y, Cw L, Jones P, Wang C, Fan Y. Effect of Statins on COPD: A Meta-Analysis of Randomized Controlled Trials. Chest. 2017;152(6):1159–1168.
    1. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest. 1983;71(6):1854–1866.
    1. Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013;381(9867):639–650.
    1. Neeland IJ, Patel RS, Eshtehardi P, et al. Coronary angiographic scoring systems: an evaluation of their equivalence and validity. Am Heart J. 2012;164(4):e541:547–552.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다